WEKO3
アイテム
Up-to-date Results of Carbon-ion Radiotherapy for Prostate Cancer
https://repo.qst.go.jp/records/65008
https://repo.qst.go.jp/records/65008be3af555-99bc-4d86-a1da-234fbcf09d1d
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2013-05-23 | |||||
| タイトル | ||||||
| タイトル | Up-to-date Results of Carbon-ion Radiotherapy for Prostate Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Nomiya, Takuma
× Nomiya, Takuma× Tsuji, Hiroshi× Maruyama, Katsuya× Kamada, Tadashi× 野宮 琢磨× 辻 比呂志× 丸山 克也× 鎌田 正 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The carbon ion radiotherapy (C-ion RT) for the prostate cancer was started in 1995 using the Heavy-Ion Medical Accelerator in Chiba (HIMAC) at the National Institute of Radiological Sciences (NIRS), Japan. After preceding phase I/II dose escalation studies of 20 fractions over 5 weeks, a phase II study was initiated in April 2000 using the treatment techniques and the recommended dose fractionation established by the phase I/II studies. This study was also successfully completed in October 2003 when the C-ion RT for the solid tumors including the prostate cancer was approved as'Advanced Medicine'from the Ministry of Health, Labor, and Welfare. Since then more than 1,400 patients have treated with carbon-ion radiotherapy as of February 2012 and advancement of hypofractionation has been also achieved. In this paper, treatment outcomes in 1,144 patients who underwent the established C-ion RT between April 2000 and July 2012 were analyzed. Out of 1,144 patients, more than 50% patients were categorized as high-risk group with T3 clinical stage, Gleason's score of 8 or higher, or PSA of 20 or higher. The 5-year overall survival rate and biochemical relapse free rate of the entire group was 95.7% and 91.0%, respectively. T-stage, Gleason score was significant prognostic factors for both the biochemical control and patient survival and initial PSA was also a predictive factor for survival. Regarding the late radiation toxicity, incidence of rectal toxicity of grade 2 or worse was 1.1% and that of genitourinary toxicity was 6.5%, respectively. In addition, incidence of the toxicity in the patients treated with more hypofractionated C-ion RT of 16 fractions over 4 weeks were lower than those of 20 fraction treatment. These favorable outcomes can be thought as apparent evidence of physical and biological advantages of the hypofractionated C-ion RT. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Heavy Ion in Therapy and Space Radiation Symposium 2013(HITSRS2013) | |||||
| 発表年月日 | ||||||
| 日付 | 2013-05-18 | |||||
| 日付タイプ | Issued | |||||
